These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 21992031)

  • 21. Meeting the MIST regulations: human metabolism in Phase I using AMS and a tiered bioanalytical approach.
    Lappin G; Seymour M; Gross G; Jørgensen M; Kall M; Kværnø L
    Bioanalysis; 2012 Feb; 4(4):407-16. PubMed ID: 22394141
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A simple liquid chromatography-tandem mass spectrometry method to determine relative plasma exposures of drug metabolites across species for metabolite safety assessments.
    Gao H; Deng S; Obach RS
    Drug Metab Dispos; 2010 Dec; 38(12):2147-56. PubMed ID: 20847138
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HPLC/ICP-MS in combination with "reverse" online isotope dilution in drug metabolism studies.
    Meermann B; Hulstaert A; Laenen A; Van Looveren C; Vliegen M; Cuyckens F; Vanhaecke F
    Anal Chem; 2012 Mar; 84(5):2395-401. PubMed ID: 22304524
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Approaches to the assessment of stable and chemically reactive drug metabolites in early clinical trials.
    Baillie TA
    Chem Res Toxicol; 2009 Feb; 22(2):263-6. PubMed ID: 19216579
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Are multimetabolite methods fit-for-purpose for supporting toxicology studies?
    Smith G
    Bioanalysis; 2011 Dec; 3(24):2701-4. PubMed ID: 22185267
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The inspection of drug metabolism and pharmacokinetic studies.
    Dent NJ
    Qual Assur; 1992 Jun; 1(3):230-6. PubMed ID: 1344678
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Juvenile animal testing in drug development--is it useful?
    Baldrick P
    Regul Toxicol Pharmacol; 2010; 57(2-3):291-9. PubMed ID: 20350578
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Pharmacokinetic and metabolic studies in the development of drugs].
    Vereczkey L
    Acta Pharm Hung; 1995 Jul; 65(4):105-11. PubMed ID: 7572191
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety assessment of drug metabolites: Characterization of chemically stable metabolites.
    Humphreys WG; Unger SE
    Chem Res Toxicol; 2006 Dec; 19(12):1564-9. PubMed ID: 17173369
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Integrated strategies for assessment of metabolite exposure in humans during drug development: analytical challenges and clinical development considerations.
    Zhu M; Zhang D; Zhang H; Shyu WC
    Biopharm Drug Dispos; 2009 May; 30(4):163-84. PubMed ID: 19544287
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Altered disposition of drugs in acute renal failure rat models: drug development strategies and perspectives.
    Srinivas NR
    Arzneimittelforschung; 2010; 60(12):731-48. PubMed ID: 21265465
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization of cyanide-trapped methylated metabonates formed during reactive drug metabolite screening in vitro.
    Rousu T; Tolonen A
    Rapid Commun Mass Spectrom; 2011 May; 25(10):1382-90. PubMed ID: 21504003
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metabolites and safety: What are the concerns, and how should we address them?
    Smith DA; Obach RS
    Chem Res Toxicol; 2006 Dec; 19(12):1570-9. PubMed ID: 17173370
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Exploring the feasibility of using the DBS technique for metabolite radioprofiling.
    Wang L; Zeng Z; Emmons G
    Bioanalysis; 2010 Aug; 2(8):1365-71. PubMed ID: 21083337
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovering drugs through biological transformation: role of pharmacologically active metabolites in drug discovery.
    Fura A; Shu YZ; Zhu M; Hanson RL; Roongta V; Humphreys WG
    J Med Chem; 2004 Aug; 47(18):4339-51. PubMed ID: 15317447
    [No Abstract]   [Full Text] [Related]  

  • 36. Application of quantitative NMR in pharmacological evaluation of biologically generated metabolites: implications in drug discovery.
    Mutlib A; Espina R; Vishwanathan K; Babalola K; Chen Z; Dehnhardt C; Venkatesan A; Mansour T; Chaudhary I; Talaat R; Scatina J
    Drug Metab Dispos; 2011 Jan; 39(1):106-16. PubMed ID: 20952552
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
    Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
    Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Modern drug development by molecular- and cell-biological methods].
    Döhmer J
    ALTEX; 2001; 18(1):9-12. PubMed ID: 11248843
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Current and future trends in the application of HPLC-MS to metabolite-identification studies.
    Castro-Perez JM
    Drug Discov Today; 2007 Mar; 12(5-6):249-56. PubMed ID: 17331890
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Strategies for dealing with metabolite elucidation in drug discovery and development.
    Nassar AE; Talaat RE
    Drug Discov Today; 2004 Apr; 9(7):317-27. PubMed ID: 15037231
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.